Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US

INTRODUCTION: Patients with Clostridioides difficile infection (CDI) often experience recurrences (rCDI), which are associated with high morbidity, mortality, and healthcare expenditures. REBYOTA™ (fecal microbiota, live-jslm [FMBL]) is a microbiota-based live biotherapeutic approved for the prevent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lodise, Thomas, Guo, Amy, Yang, Min, Cook, Erin E., Song, Wei, Yang, Danni, Wang, Qingyuan, Zhao, Angela, Bochan, Markian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219864/
https://www.ncbi.nlm.nih.gov/pubmed/37093360
http://dx.doi.org/10.1007/s12325-023-02506-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219864/
https://www.ncbi.nlm.nih.gov/pubmed/37093360
http://dx.doi.org/10.1007/s12325-023-02506-0

Ejemplares similares